Protein NMB1125 and use thereof in pharmaceutical formulations

Use of a novel vaccine antigen applied in a preventive or therapeutic way against diseases in general, being such disease of bacterial, viral, cancer related, or other origin. The technical objective that this invention pursues is the development of formulations with the ability to increase the protective spectrum of existing vaccines and hence expanding it against different pathogens. In order to achieve this goal the NMB1125 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally, the gene codifying for NMB1125 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in animal models. The sequence data from homologous genes showed, due to the high degree of conservation, its high value as a target antigen of a cross-reactive response when it is presented by different routes. Resultant formulations of this invention are of use in the pharmaceutical industry as vaccine formulations for human use.